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New Oral Antithrombotic Drugs
Vana Christopoulou-Cokkinou, MD
A B S T R A C T
New oral antithrombotic drugs are currently used for several indications, but mostly 
for the long-term treatment or prevention of thromboembolic disease in situations 
such as high-risk orthopedic surgery, deep vein thrombosis and myocardial infarc-
tion. They are also used in atrial fibrillation for the prevention of stroke. This family 
of drugs includes anti-platelet agents, eg. ticlopidine and clopidogrel, antithrombin 
agents, eg. ximelagatran and several others with various mechanisms of action. Oral 
intake has to fulfill certain conditions regarding absorption, efficacy and safety.
Orally administered antithrombotic agents are the most appropriate and, therefore, 
the most commonly recommended drugs used for long-term treatment and prophylaxis 
against both venous and arterial thrombotic events.
The expansion of indications for antithrombotic agents is the result of an ever-
growing population of patients in need of treatment or prevention against thrombo-
embolic disease.
Venous thrombosis, and, in particular, its commonest presentation, deep vein 
thrombosis (DVT), usually develops during conditions favoring venous blood stasis, 
usually in the legs. The pathogenetic mechanism is triggered by vascular endothelial 
injury and activation of the coagulation cascade followed by thrombin generation, 
which in turn leads to platelet adhesion and aggregation. Among the risk factors as-
sociated with venous thrombosis are extended periods of bed-confinement, trauma, 
fractures, obesity, malignancy, old age, surgical procedures such as high risk abdominal 
surgery, gynecological, cardiovascular, and, in particular, orthopedic procedures such 
as hip and/or knee replacements, which are most commonly associated with DVT and 
pulmonary embolism.
Arterial thrombosis is usually triggered by an already damaged arterial endothe-
lium mostly due to atheromatous changes which become the focus of thrombogenesis 
in a high-shear environment. The initial event attracts at first platelets with subsequent 
mobilization of the coagulation cascade which in turn results in thrombin generation 
and, finally, fibrin formation. Among the pathological conditions associated with arte-
rial thrombosis are hypertension, diabetes and hyperlipidemia. Arterial thrombosis 
is usually manifested as coronary, cerebral or peripheral ischemic vascular events. In 
both venous and arterial thrombosis, congenital thrombophilia or acquired hyper-
coagulable states may also be the causative or the aggravating factors for abnormal 
thrombogenesis.
The problem is serious and its magnitude is impressive if one considers that in 
the USA DVT is responsible for 250,000/year hospitalizations and pulmonary em-
bolism is the cause of 12% of hospital deaths [1]. Other statistical data confirm that, 
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among Caucasians, 1/1000/year experience their first DVT 
[2], 1.3-4.1/1000/year have their first cerebral episode [3] and 
5/ 1000/year suffer their first myocardial infarction. The risk 
of thromboembolic disease increases with age; it increases 
by 3 to 5 times in individuals aged 70 years or more, whereas 
atrial fibrillation, a condition closely related to old age, not 
only maintains a prominent position among the conditions 
requiring antithrombotic treatment, but it is also undertreated 
due to poor judgment and non-compliance with established 
guidelines, both on the patients’ part as well as on the part 
of the physicians [4].
It is obvious that antithrombotic treatment is needed not 
only during the acute phase of thrombotic events but also for 
long-term prevention. It is this particular factor, i.e. time, that, 
in some cases, makes the use of oral antithrombotic substan-
ces indispensable.
At present, 0.7% of the “western” population is under oral 
antithrombotic treatment [5]. In table 1 are listed the most 
common antithrombotic agents currently in use, with their 
main sites of action and routes of administration. They may 
belong to the groups of anti-platelet or anti-thrombin agents, 
whereas a group labeled “miscellaneous” includes agents ex-
ercising their action in other less commonly considered sites. 
They can also have a direct or indirect mechanism of action 
and they can be administered through the oral or parenteral 
route.
The present article will present a brief account of the 
recently developed, orally administered antithrombotic 
agents.
1 .  A N T I - P L A T E L E T  A G E N T S
For several decades, nearly a century, aspirin has been 
holding a strong position as an oral antiplatelet drug. It has also 
been serving as a reference drug to which many other newly 
developed agents (not only antiplatelet drugs) are compared. 
Its mechanism of action is based on its interference with 
arachidonic acid metabolism, i.e. the inactivation of cyclo-
oxygenase (COX) activity, thus affecting prostaglandin syn-
thesis [6]. It blocks the generation of thromboxane (TXA2), [a 
prostaglandin, antagonistic to its relative, prostacyclin (PGI2)], 
which enhances platelet aggregation and vasoconstiction [7]. It 
is not a new but an old and everlasting antiplatelet agent, inex-
pensive, easily available, not requiring laboratory monitoring 
[except for “aspirin resistance” cases [8,9]] and with a usually 
dose-dependent antithrombotic effect and dose-dependent 
adverse effects as well.
The newly developed, oral anti-platelet drugs, ticlopi-
dine and clopidogrel, are both thienopyridines, exercising 
their antiplatelet action through the ADP receptors of the 
platelets, inhibiting ADP-induced platelet aggregation, 
with no direct effect on arachidonic acid metabolism 
TABLE 1. Available antithrombotic agents
Name Site of action Route of 
administration
A. ANTIPLATELET 
AGENTS
• Aspirin COX oral
• Dipyridamol COX oral
• Ticlopidine ADP-Receptors oral
• Clopidogrel ADP-Receptors oral
• GPIIâ/IIIa Inhibitors GPIIâ/IIIa 
Receptors
parenteral (oral?)
B. ANTITHROMBIN 
AGENTS
• Heparin (Ind) parenteral
• LMWHs (Ind)    IIa, Xa, IXa parenteral
• Danaparoid (Ind) parenteral
• Hirudin (Dir) IIa parenteral
• Argatroban (Dir) IIa parenteral
• Melagatran (Dir) IIa parenteral
• Ximelagatran (Dir) IIa oral
    AVK agents II-VII-IX-X etc oral
C. MISCELLANEOUS
• Anti-TF/VIIa TF/VIIa
• TFPI TF/VIIa
• NaPc2 TF/VIIa parenteral
• Danaparoid Xa
• Fondaparinux (Ind) Xa
• Idraparinux (Ind) Xa
[10,11]. It seems, especially in the case of clopidogrel, that 
the crucial point in their mechanism of action is the irre-
versible reduction of the number of ADP-binding sites on 
the platelet surface [12], with a dose- and time-dependent 
accumulative effect [13].
Ticlopidine, orally administered, in the usual dose of 
250 mg/day, has a satisfactory absorption of approximately 
90% and a peak plasma concentration of 1-3 hours after 
intake. Repeated dosage causes an accumulation of the 
substance, thus tripling its plasma concentration at the end 
of a 3-week bid treatment. However, 98% of the drug is 
bound to plasma proteins [13]. Its T/2 varies from 24 to 36 
hours after a simple oral dose to 96 hours after a 2-week 
repeated administration, usually of 250 mg bid and its de-
layed effect is a negative feature when rapid antiplatelet 
action is required [14].
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The drug has been evaluated (STIMS, CATS, TASS 
studies) in patients with stroke, transient cerebral isch-
emia, unstable angina, myocardial infarction and inter-
mittent claudication, as well as in cases of aortocoronary 
bypass surgery [15-19]. It is more effective than aspirin, 
even though marginally; the initial indications referred to 
patients not tolerating aspirin [14]. The combination of ti-
clopidine and aspirin proved to be superior to aspirin alone 
or to aspirin and warfarin combined, particularly for the 
prevention of thrombotic complications after coronary ar-
tery stent placement [20]. However, its high cost combined 
with its slow onset and slow action decrease, and, mainly, 
its toxic effect on bone marrow resulting in leukopenia and 
thrombocytopenia, led to the practical withdrawal of the 
drug, particularly after the detection of the occurrence 
of thrombotic thrombocytopenic purpura (TTP) in some 
cases. TTP, although rare (0,02%), is associated with a high 
mortality rate (20%) [21], and was the triggering factor 
for the gradual abandonment of the substance in favor of 
clopidogrel [22].
Clopidogrel, an agent inactive in vitro, when orally 
administered, is transformed in the liver into its active 
metabolite (SR 26334) with a T/2 of approximately 8 hours 
[23]. The impact of a possible liver function impairment 
on clopidogrel metabolism and effectiveness has not been 
evaluated yet. However, there is an obvious interindividual 
variability in its metabolic activation leading to the hypoth-
esis that the P450 isoenzymes CY P3A4 and – 3A5 metabo-
lize the drug much faster than other similar isoenzymes 
do, and that these are the ones probably responsible for 
the metabolism of some statins as well, namely atorvastatin 
[24]. In fact, it seems that the simultaneous administration 
of clopidogrel and atorvastatin (but not pravastatin) alters 
the efficacy of the drug, causing a “clopidogrel resistance” 
effect, although the phenomenon has been questioned by 
some [25-28].
ADP-induced platelet aggregation is inhibited by clopi-
dogrel in a usual pattern of a daily dose of 100-200 mg, 
whereas a loading dose of 300-600 mg is recommended 
by some to be taken orally immediately before the per-
formance of percutaneous coronary intervention (PCI) 
[29].
Clopidogrel was tested in limited phase II studies and 
in an extensive phase III trial. The CAPRIE study [30] 
included 6400 patients in total with an increased risk of 
recurrent ischemic events. 75 mg/day of clopidogrel versus 
325 mg/day of aspirin were compared. The patients suf-
fering from symptomatic peripheral arterial disease were 
the ones that benefited the most from clopidogrel, even 
though the overall conclusion showed a marginally supe-
rior effectiveness of the drug over aspirin. Hemorrhagic 
complications were similar (9,3%) in both groups and no 
bone marrow toxicity from clopidogrel was detected. The 
drug has been, therefore, judged to be appropriate for use 
in symptomatic patients with peripheral atherosclerotic 
disease.
The complementary inhibitory activities of clopidogrel 
and aspirin on the platelets were evaluated in the CURE 
trial [31,32]. In it, more than 12,000 patients suffering 
from acute (less than 24 hour-duration) coronary syndro-
mes with no ST-elevation were included. They received an 
initial loading dose (300 mg) of clopidogrel followed by a 
combination of aspirin (doses varied: 75-325 mg/day) and 
clopidogrel (75 mg/day) or aspirin and placebo for a period 
of 3-12 months. Clopidogrel combined with aspirin had 
a superiority in effectiveness, lasting even after the first 
month of its administration, while bleeding complications 
were increased in that group (3,7% versus 2,7%) and were 
related to the higher doses of aspirin [33]. Finally, the 
cost-effectiveness of such an approach of long duration 
has been investigated [34].
It has also been shown that long-term intervals (one 
year) of treatment with clopidogrel reduced the risk of post-
PCI vascular events and established the combination of 
aspirin and clopidogrel as a standard post-coronary-stent-
placement treatment for a period of one month [35].
In the CREDO study [36], it was observed that a longer 
interval before the clopidogrel loading dose (300 mg 3 hrs 
and, preferably 6 hours pre-PCI) reduced the post-PCI 
thrombotic events.
In the CLARITY and CLARITY-TIMI-28 trials it was 
shown that clopidogrel was both effective and cost-effective 
in acute coronary syndromes and in patients with ST-seg-
ment elevation myocardial infarction, but probably also as 
part of the reperfusion regimen in patients with myocardial 
infarction undergoing thrombolysis [37-39].
The accumulated evidence of the benefits from the ad-
dition of aspirin to clopidogrel in the secondary preven-
tion of ischemic stroke on one hand and of the increased 
bleeding risk on the other, led to the MATCH study [37]. 
It is a randomized, double-blind, placebo-controlled trial 
comparing aspirin combined with clopidogrel and clopi-
dogrel alone in patients with a recent ischemic stroke or 
cerebral attack in high risk patients. 7599 individuals were 
included in the study, which lasted for 18 months, and the 
final conclusion was that the difference in reducing major 
vascular events by the addition of aspirin to clopidogrel 
was non-significant, whereas the risk of life-threatening 
major bleeding events was increased [40-42].
Even so, the last word in this field has not been pro-
nounced yet, since the inhibition target of the two drugs, 
ticlopidine and clopidogrel, is only one of the three known 
platelet ADP receptors, the P2Y receptor (the other two 
being P2YA and P2YAC). Even through this limited inhibi-
tion, their superiority over aspirin is evident [43,44]. It 
is, therefore, reasonable to expect in the future a further 
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development of more potent similar agents.
A parallel development may be expected from the group 
of substances against platelet thrombin receptors, namely 
the PAR-1 receptor (there are three more: PAR-2, PAR-3 
and PAR-4). Experiments on animals are not yet completed 
and the possibility of such an agent being effective through 
the oral route cannot be excluded [45,46].
Finally, the integrin IIbâ3/GPIIb/IIIa antagonists, at 
present, are in use only parenterally. They belong to various 
categories such as monoclonal antibodies (abciximab), nat-
ural inhibitors (RGD-disintegrins) with the Lys-Gly-Asp 
peptide sequence, or synthetic ones (KGD) such as eptifiba-
tide and tirofiban with the Arg-Gly-Asp peptide sequence. 
These RGD sequences are responsible for fibrinogen, von 
Willebrand factor or fibronectin-binding [47].
The indications for the use of these agents are mainly 
unstable angina and PCI [48]. Attempts have been made 
for their structural alteration into non-peptide forms that 
could be easily absorbed through the gastrointestinal tract. 
However, in spite of the initial optimism regarding their 
efficacy superiority over aspirin and the hope to overcome 
the need for laboratory monitoring, the outcome of clini-
cal studies was disappointing. The results of the trials on 
orbofiban (OPUS), sibrafiban (SYMPHONY), xemifiban 
(EXCITE) and lotrafiban (BRAVO), which included more 
than 40.000 patients with acute coronary events, could not 
be adequately evaluated [49-52]. In fact, a meta-analysis of 
these trials showed that, when taken orally, these agents 
were not indeed more effective than aspirin, nor superior 
to a placebo when combined with aspirin. Their efficacy 
proved to be dependent on high doses, which also caused 
a high frequency of bleeding as well [53].
A very serious outcome, in addition to the above, was 
an alarmingly increased mortality rate observed in some 
cases [54]. This was an unexpected unfortunate event and 
its magnitude could not be neglected (31%), therefore an 
explanation was sought. Among the several possible mecha-
nisms examined were the unexpected, in some individuals, 
activation of platelets or excessive fibrinogen binding by 
those ligands initially designed to block them. It also seems 
that the limited extent of phase II trials proved insufficient 
to provide the data necessary, in phase III trials, for the 
establishment of a dose-dependent response, a correlation 
with bleeding complications and a disengagement from 
laboratory monitoring [49-58].
2 .  A N T I T H R O M B I N  A G E N T S
This large group (table 1) includes substances that inhibit 
thrombin only, or thrombin primarily, in addition to other 
coagulation factors (eg: fIX, fX etc). They exercise their action 
indirectly, mainly through ATIII, like the heparins (UFH, 
LMWHs) or directly, like hirudin and related substances. As 
to their route of administration, it can be oral or parenteral.
Our interest will be focused on new oral antithrombins.
As a general rule, the polypeptidic nature of many anti-
thrombotic agents does not allow their satisfactory use through 
the oral route. Therefore, ways have been looked for to make 
them easily absorbable and subsequently efficient. Some of 
them are: molecule size reduction (eg: argatroban, napsa-
gatran, inegatran, melagatran etc), and molecular synthesis 
alterations. In fact, some properties that seem to be needed 
in order to make a substance suitable for oral antithrombotic 
use are discussed, as illustrated by the 5 points of the Lipin-
ski rule [59,60]. Among them are a low molecular weight, 
preferably below 500 D, an oligopeptide molecular synthesis 
(tripeptides are preferable to pentapeptides), a specific ami-
noacid sequence (eg: D-Phe-Pro-Arg-Chloromethyl-Ket) etc. 
The above appear to contribute to the high bioavailability and 
efficacy of a substance once it has successfully crossed the GI 
tract barrier into the blood circulation.
A good example of the use of a “carrier” or “delivery” 
molecule helping the active substance to be actually carried 
towards its target is the UFH/ SNAC complex. Heparin, 
when combined with SNAC (N-8-2-sodium-hydroxybenzoyl-
amino-carzylate) as a delivery substance, since it facilitates 
translipid transport of UFH through gastric mucosa [61], is 
easily absorbed when taken orally, and can thus reach theapeu-
tic plasma levels. The first steps of this agent’s trials have been 
made. In a comparative study [62], UFH (5000 U subcut) 
versus UFH/SNAC in two scales of oral dosages (60.000 U/1,5 
gr or 90.000 U/2,25 gr, tid) administered post-operatively in 
123 patients submitted to hip- or knee-arthroplasty, proved 
encouraging. Although aPTT was in fact prolonged, anti-Xa 
activity was preferably used for laboratory monitoring. Multi-
center studies then followed: in 124 centers worldwide, a total 
of 2,264 patients submitted to knee arthroplasty were given 
the complex. It was administered every 4-6 hours for 27-30 
days postoperatively, and was compared to a LMWH under 
no laboratory monitoring [63].
Further data on UFH/SNAC are pending at present.
The need for pharmaceutical substances with an effective 
antithrombotic action, in no need of laboratory monitoring, 
free of adverse effects, easily obtainable and easily admin-
istered through the oral route, in summary, appropriate for 
long-term antithrombotic treatment / prevention, has long 
generated research activities, stimulating both clinicians and 
basic scientists. So far, the properties of such an “ideal” agent 
have been found only in part. The already existing substances 
in use have only partly satisfied the above mentioned expecta-
tions, since, in addition to the efficacy of the classical, long-
time used antithrombotic agents, a series of limitations has 
emerged stimulating the search for such novel agents.
These limitations are listed in tables 2 and 3 and refer to 
the main antithrombotic agents used at present, both orally 
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(warfarin) and parenterally (UFH, LMWH).
Vitamin K antagonists (VKA), such as warfarin, have 
been in use for more than 60 years. They are administered 
orally and their antithrombotic action lies on their inhibition 
of the vitamin K-dependent coagulation factors (II, VII, IX, 
X) which is dose- and time-dependent. The need for labora-
tory monitoring, targeting to an INR of 2-3, and their narrow 
therapeutic range, as well as the dietary and pharmaceutical 
interference with their action, along with their adverse effects, 
triggered a need for the development of new similar drugs free 
of the above restrictions while exhibiting the desired qualities 
of VKA’s and heparins.
Such a new drug is ximelagatran. It is a novel, orally ad-
ministered antithrombotic substance, in fact a pro-drug, the 
inactive form of melagatran, the active direct antithrombin 
inhibitor [64]. Since melagatran is not absorbed though the 
GI tract, via a slight modification of its molecule, ximelaga-
tran has been developed. Its absorption is quick, about 20 
minutes, and its metabolism lies in the liver and is not affected 
by age or gender nor by simultaneous consumption of food 
or other drugs. Among ximelagatran’s metabolites (eg: ethyl-
melagatran, OH-melagatran) rapidly excreted is melagatran 
(20%), an at least 100 times more potent agent, which directly 
inhibits plasma thrombin as well as thrombin trapped by the 
thrombus [65,66].
The T/2 of unmetabolized ximelagatran is 0,34 hrs and, 
when transformed to melagatran, 3-4 hrs. Its peak action 
is manifested in 2 hours, this being much superior to the 
one of hirudin [67-70]. Other actions include inhibition of 
the thrombin/thrombomodulin complex, interference with 
fibrinogen, protein C, platelets and fibrinolysis [71,72]. It 
is excreted through the kidneys and its activity reflects, to 
a certain degree, the renal function, an important factor 
in elderly patients [73]. In cases of renal impairment its 
dosage needs to be readjusted [74]. The substance has a 
satisfactory bioavailability since only 15% of it is bound 
to plasma proteins. Its dose-effect relation is predictable 
and its administration does not depend on laboratory mo-
nitoring even though it affects aPTT and ECT (ecarin 
clotting time) according to a predictable linear pattern 
[75,76].
Ximelagatran has been extensively tried through several 
grand scale clinical studies including a total of about 35.000 
individuals. The initial studies were directed toward throm-
boprophylaxis of patients undergoing orthopedic surgery, such 
as knee and/or hip replacement (METHRO, EXPRESS) in 
which ximelagatran was given orally either alone or following 
parenteral melagatran, and its use was compared to warfarin 
or LMWHs [77-80].
These were followed by studies in DVT cases with or 
without pulmonary embolism [THRIVE,81,82], myocardial 
infarction [ESTEEM, 83] and atrial fibrillation (AF) for the 
prevention of stroke [84].
Of particular interest is the indication for ximelagatran 
in cases of non-valvular AF. It affects mostly elderly people, 
under conditions of diminished compliance and increased risk 
for stroke or cerebral hemorrhage if antithrombotic treatment 
is not achieved. Its prevalence magnitude is also impressive 
[85] since only in the USA it affects 22 million adults and 
more than 46.000 new cases/year are diagnosed in the UK. 
Independent risk factors are those, already mentioned, as-
sociated with arterial thrombosis and, in particular, male 
sex, hypertension, valvular heart disease and advanced age. 
Age is a determinant factor since, after the age of 50, each 
additional decade doubles AF prevalence, whereas rheumatic 
valvular disease increases the risk of stroke 18-fold. Preventive 
antithrombotic treatment is considered mandatory in elderly 
patients (over 75 years) and especially those with at least one 
additional risk factor. It has to be ardent (so far with warfarin 
and not just aspirin) and carefully monitored [86].
There has been a series of clinical studies, at least five, 
with ximelagatran for AF. Of these, the combined results of 
SPORTIF III and SPORTIF V allow us to draw the final 
conclusions on the treatment profile of the drug: it seems 
that there is no significant efficacy between ximelagatran and 
well monitored warfarin for AF (0.03% difference of stroke 
incidence). However, if hemorrhagic events and the presence 
or absence of laboratory monitoring are taken into account, 
effectiveness and safety of ximelagatran, in the absence of 
laboratory monitoring, as compared to warfarin, is evident 
[85-87]. The usual dose is 36 mg bid for a period of 4-6 weeks, 
sometimes even for one to two years [84].
TABLE 2. Limitations of heparin
• Indirect action (ATIII)
• Protein binding
• Limited bioavailability
• PF4 binding
• Non predictable dose-effect relation
• Narrow therapeutic range
• Laboratory monitoring
TABLE 3. Limitations of AVK
• Slow onset/end of action
• Food/drug interference
• Genetic particularities in metabolism
• Non predictable dose-effect relation
• Narrow therapeutic range
• Laboratory monitoring
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A possible limitation of the drug is the occurrence, in 
4-10% of patients taking it for 6 weeks to 4 months, of a 
transient, reversible and asymptomatic increase in alanine 
aminotransferase (ALT) levels. Even so, more information 
is needed to investigate the phenomenon, benign as it seems 
to be [83].
Recently it was reconfirmed [88] that elevation of ALT 
levels occurring within the first 6 months of treatment, affects 
the 7,9% of patients and is mainly asymptomatic. However, 
a close follow-up of these patients according to a recently 
developed algorithm helps to ensure that the probable hepatic 
risk is minimal.
Another new oral direct anti-thrombin agent is being cur-
rently evaluated. Dabigatran etexolate (BIBR 1048) is being 
investigated in a multicenter, parallel-group, double blind 
study of 1,973 patients undergoing hip- or knee-replacement 
surgery [the BISTRO trial, 88]. Its dosage and treatment escala-
tion have been compared to LMWHs for the prevention of 
DVT in orthopedic surgery. Further information on the use 
of this new drug is needed.
3 .  M I S C E L L A N E O U S  A N T I T H R O M B O T I C  
A G E N T S  A C T I N G  I N  V A R I O U S  S I T E S
There are certainly other antithrombotic agents acting in 
several other sites of the thrombogenesis process, which could 
possibly be administered orally.
Some are already known for their parenteral use, such as 
the TF/f.VIIa complex [89], TFPI, NaPC2, inhibitors of factors 
IX or X, such as fondaparinux and idraparinux are already 
being studied for a possible oral use [90], and also inhibitors 
of the intrinsic pathway, or interfering with protein C pathway 
or fibrinolysis [91].
Of these, the interest is focused predominantly on the f. 
Xa inhibitors. The aim has been to develop short-molecule 
direct anti-Xa substances easy to administer. Idraparinux and 
fondaparinux are such agents and the AMADEUS and Van 
Gogh PE, Van Gogh DVT and Van Gogh Ext phase III studies 
focus on patients with atrial fibrillation, pulmonary embolism 
and deep vein thrombosis [92]. Simultaneously, such orally 
administered, drugs are being developed either by molecular 
ligand modifications [93] through the use of a “prodrug” 
strategy [94] or dealing with non-peptide agents [95].
Potentially promising results are expected on the oral 
use of a novel direct f. Xa inhibitor, BAY 59-7939, which 
seems to express an enormous affinity for f. Xa rather than 
for other serine proteases and will be tried in venous and 
arterial thromboses [96].
The research area is certainly bursting with activity, indi-
cating that the desired target, the use of an oral, effective, safe, 
easy to take antithrombotic agent will soon be achieved.
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